ArticleCancer gene therapy2014

Use of monitoring levels of soluble forms of cytokeratin 18 in the urine of patients with superficial bladder cancer following intravesical Ad-IFNα/Syn3 treatment in a phase l study.

W F Benedict et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.